Sichuan Hebang Biotechnology Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 4/6
Sichuan Hebang Biotechnology has a total shareholder equity of CN¥19.4B and total debt of CN¥3.4B, which brings its debt-to-equity ratio to 17.6%. Its total assets and total liabilities are CN¥26.0B and CN¥6.6B respectively. Sichuan Hebang Biotechnology's EBIT is CN¥572.4M making its interest coverage ratio -9. It has cash and short-term investments of CN¥2.6B.
Wichtige Informationen
17.6%
Verhältnis von Schulden zu Eigenkapital
CN¥3.41b
Verschuldung
| Zinsdeckungsgrad | -9x |
| Bargeld | CN¥2.57b |
| Eigenkapital | CN¥19.38b |
| Gesamtverbindlichkeiten | CN¥6.59b |
| Gesamtvermögen | CN¥25.98b |
Jüngste Berichte zur Finanzlage
Recent updates
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled
Sep 25
Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story
Aug 16Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing
Jun 04Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)
May 13Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?
Mar 07Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock
Apr 21Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 603077's short term assets (CN¥10.8B) exceed its short term liabilities (CN¥5.8B).
Langfristige Verbindlichkeiten: 603077's short term assets (CN¥10.8B) exceed its long term liabilities (CN¥832.3M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 603077's net debt to equity ratio (4.4%) is considered satisfactory.
Schulden abbauen: 603077's debt to equity ratio has increased from 15.7% to 17.6% over the past 5 years.
Schuldendeckung: 603077's operating cash flow is negative, therefore debt is not well covered.
Zinsdeckung: 603077 earns more interest than it pays, so coverage of interest payments is not a concern.